{"altmetric_id":6052445,"counts":{"readers":{"mendeley":39,"citeulike":0,"connotea":0},"total":{"posts_count":2},"news":{"unique_users_count":1,"unique_users":["la_times_science_now"],"posts_count":1},"twitter":{"unique_users_count":1,"unique_users":["ile_para"],"posts_count":1}},"citation":{"altmetric_jid":"4f6fa63a3cf058f610008b59","authors":["Axel S. Merseburger","Gabriel P. Haas","Christoph-A. von Klot"],"doi":"10.1177\/1756287214555336","first_seen_on":"2016-03-04T13:02:59+00:00","issns":["1756-2872"],"issue":"1","journal":"Therapeutic Advances in Urology","last_mentioned_on":1460910437,"links":["http:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC4294802\/"],"pmcid":"PMC4294802","pmid":"25642291","pubdate":"2015-02-01T00:00:00+00:00","publisher":"SAGE Publications","startpage":"9","title":"An update on enzalutamide in the treatment of prostate cancer","type":"article","volume":"7","mendeley_url":"http:\/\/www.mendeley.com\/research\/update-enzalutamide-treatment-prostate-cancer"},"altmetric_score":{"score":11,"score_history":{"1y":0,"6m":0,"3m":0,"1m":0,"1w":0,"6d":0,"5d":0,"4d":0,"3d":0,"2d":0,"1d":0,"at":11},"context_for_score":{"all":{"total_number_of_other_articles":7560115,"mean":6.5270342886323,"rank":656716,"this_scored_higher_than_pct":91,"this_scored_higher_than":6894756,"rank_type":"exact","sample_size":7560115,"percentile":91},"similar_age_3m":{"total_number_of_other_articles":283521,"mean":10.778328520034,"rank":36477,"this_scored_higher_than_pct":86,"this_scored_higher_than":246628,"rank_type":"exact","sample_size":283521,"percentile":86},"this_journal":{"total_number_of_other_articles":80,"mean":4.1040253164557,"rank":9,"this_scored_higher_than_pct":88,"this_scored_higher_than":71,"rank_type":"exact","sample_size":80,"percentile":88},"similar_age_this_journal_3m":{"total_number_of_other_articles":4,"mean":0.95,"rank":1,"this_scored_higher_than_pct":75,"this_scored_higher_than":3,"rank_type":"exact","sample_size":4,"percentile":75}}},"demographics":{"poster_types":{"member_of_the_public":1},"users":{"twitter":{"cohorts":{"Members of the public":1}},"mendeley":{"by_status":{"Professor > Associate Professor":2,"Student  > Doctoral Student":4,"Researcher":8,"Student  > Ph. D. Student":5,"Student  > Postgraduate":3,"Other":9,"Student  > Master":3,"Student  > Bachelor":3,"Lecturer":1,"Professor":1},"by_discipline":{"Medicine and Dentistry":20,"Neuroscience":1,"Economics, Econometrics and Finance":1,"Agricultural and Biological Sciences":8,"Business, Management and Accounting":1,"Biochemistry, Genetics and Molecular Biology":4,"Mathematics":2,"Unspecified":1,"Pharmacology, Toxicology and Pharmaceutical Science":1}}},"geo":{"twitter":{"IT":1},"mendeley":{"BR":1,"DK":1}}},"posts":{"news":[{"title":"UCLA will get hundreds of millions for rights to prostate cancer drug","url":"http:\/\/ct.moreover.com\/?a=25690536576&p=1pl&v=1&x=EsO_qHOIbMFRMIm5JQczmg","license":"public","citation_ids":[6052445],"posted_on":"2016-03-04T13:00:00+00:00","summary":"A prostate cancer drug developed at UCLA will provide hundreds of millions of dollars for research under a record-setting deal announced Friday by university officials.","author":{"name":"LA Times","url":"http:\/\/www.latimes.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/625\/normal\/Screen_Shot_2016-01-26_at_10.32.49.png?1453804385"}}],"twitter":[{"url":"http:\/\/twitter.com\/ile_para\/statuses\/721736802520981504","license":"gnip","citation_ids":[6052445],"posted_on":"2016-04-17T16:27:17+00:00","author":{"name":"ile parascandolo","url":"http:\/\/www.ilcielooltrevenere.com","image":"https:\/\/pbs.twimg.com\/profile_images\/907587406580371457\/AHPwgrUZ_normal.jpg","description":"medico, senologa palliativista dietoncologa presid.ass. volontariato oncologia il cielo oltre Venere.Md breast cancer nutritionist and cancer pain Specialist","id_on_source":"ile_para","tweeter_id":"500571911","geo":{"lt":40.83333,"ln":14.25,"country":"IT"},"followers":82},"tweet_id":"721736802520981504"}]}}